Regulation of DEK expression by AP-2α and methylation level of DEK promoter in hepatocellular carcinoma

Oncology Reports

Volumn 36, Issue 4, 2016, Pages 2382-2390

  Qiao, Ming Xu ^a   Li, Chun ^a   Zhang, Ai Qun ^b   Hou, Ling Ling ^a   Yang, Juan ^a   Hu, Hong Gang ^a  

^a BEIJING JIAOTONG UNIVERSITY   (China)

^b CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Ap 2 ; DEK promoter; Hepatocellular carcinoma; Methylation; Transcriptional regulation

Indexed keywords

TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR AP 2ALPHA; UNCLASSIFIED DRUG; DEK PROTEIN, HUMAN; DNA BINDING PROTEIN; NONHISTONE PROTEIN; ONCOPROTEIN; TRANSCRIPTION FACTOR AP 2;

ARTICLE; BINDING SITE; CONTROLLED STUDY; CPG ISLAND; DEK GENE; DNA METHYLATION; DOWN REGULATION; GENE; GENE ACTIVITY; GENE DELETION; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE SILENCING; HEPATOCELLULAR CARCINOMA CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL; LIVER CELL CARCINOMA; POINT MUTATION; PRIORITY JOURNAL; PROMOTER REGION; UPREGULATION; BIOSYNTHESIS; GENETICS; LIVER TUMOR; PATHOLOGY; TRANSCRIPTION INITIATION; TUMOR CELL LINE;

BINDING SITES; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CHROMOSOMAL PROTEINS, NON-HISTONE; DNA METHYLATION; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; ONCOGENE PROTEINS; PROMOTER REGIONS, GENETIC; TRANSCRIPTION FACTOR AP-2; TRANSCRIPTIONAL ACTIVATION;

EID: 84984941786     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2016.4984     Document Type: Article

References (34)

1. Raza A and Sood GK: Hepatocellular carcinoma review: Current treatment, and evidence-based medicine. World J Gastroenterol 20:4115-4127, 2014.
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127:2893-2917, 2010.
3. Perz JF, Armstrong GL, Farrington LA, Hutin YJ and Bell BP: The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 45:529-538, 2006.
4. Hu HG, Scholten I, Gruss C and Knippers R: The distribution of the DEK protein in mammalian chromatin. Biochem Biophys Res Commun 358:1008-1014, 2007.
5. Waldmann T, Baack M, Richter N and Gruss C: Structurespecific binding of the proto-oncogene protein DEK to DNA. Nucleic Acids Res 31:7003-7010, 2003.
6. Waldmann T, Eckerich C, Baack M and Gruss C: The ubiquitous chromatin protein DEK alters the structure of DNA by introducing positive supercoils. J Biol Chem 277:24988-24994, 2002.
7. Waldmann T, Scholten I, Kappes F, Hu HG and Knippers R: The DEK protein: an abundant and ubiquitous constituent of mammalian chromatin. Gene 343:1-9, 2004.
8. von Lindern M, Fornerod M, van Baal S, Jaegle M, de Wit T, Buijs A and Grosveld G: The translocation (6;9), associated with a specific subtype of acute myeloid leukemia, results in the fusion of two genes, dek and can, and the expression of a chimeric, leukemia-specific dek-can mRNA. Mol Cell Biol 12:1687-1697, 1992.
9. Soekarman D, von Lindern M, Daenen S, de Jong B, Fonatsch C, Heinze B, Bartram C, Hagemeijer A and Grosveld G: The translocation (6;9) (p23;q34) shows consistent rearrangement of two genes and defines a myeloproliferative disorder with specific clinical features. Blood 79:2990-2997, 1992.
10. Kappes F, Waldmann T, Mathew V, Yu J, Zhang L, Khodadoust MS, Chinnaiyan AM, Luger K, Erhardt S, Schneider R, et al: The DEK oncoprotein is a Su (var) that is essential to heterochromatin integrity. Genes Dev 25:673-678, 2011.
11. Fu GK, Grosveld G and Markovitz DM: DEK, an autoantigen involved in a chromosomal translocation in acute myelogenous leukemia, binds to the HIV-2 enhancer. Proc Natl Acad Sci USA 94:1811-1815, 1997.
12. McGarvey T, Rosonina E, McCracken S, Li Q, Arnaout R, Mientjes E, Nickerson JA, Awrey D, Greenblatt J, Grosveld G, et al: The acute myeloid leukemia-associated protein, DEK, forms a splicing-dependent interaction with exon-product complexes. J Cell Biol 150:309-320, 2000.
13. Alexiadis V, Waldmann T, Andersen J, Mann M, Knippers R and Gruss C: The protein encoded by the proto-oncogene DEK changes the topology of chromatin and reduces the efficiency of DNA replication in a chromatin-specific manner. Genes Dev 14:1308-1312, 2000.
14. Kavanaugh GM, Wise-Draper TM, Morreale RJ, Morrison MA, Gole B, Schwemberger S, Tichy ED, Lu L, Babcock GF, Wells JM, et al: The human DEK oncogene regulates DNA damage response signaling and repair. Nucleic Acids Res 39:7465-7476, 2011.
15. Kim DW, Chae JI, Kim JY, Pak JH, Koo DB, Bahk YY and Seo SB: Proteomic analysis of apoptosis related proteins regulated by proto-oncogene protein DEK. J Cell Biochem 106:1048-1059, 2009.
16. Lee KS, Kim DW, Kim JY, Choo JK, Yu K and Seo SB: Caspasedependent apoptosis induction by targeted expression of DEK in Drosophila involves histone acetylation inhibition. J Cell Biochem 103:1283-1293, 2008.
17. Casas S, Nagy B, Elonen E, Aventín A, Larramendy ML, Sierra J, Ruutu T and Knuutila S: Aberrant expression of HOXA9, DEK, CBL and CSF1R in acute myeloid leukemia. Leuk Lymphoma 44:1935-1941, 2003.
18. Lin L, Piao J, Gao W, Piao Y, Jin G, Ma Y, Li J and Lin Z: DEK over expression as an independent biomarker for poor prognosis in colorectal cancer. BMC Cancer 13:366, 2013.
19. Piao J, Shang Y, Liu S, Piao Y, Cui X, Li Y and Lin Z: High expression of DEK predicts poor prognosis of gastric adenocarcinoma. Diagn Pathol 9:67, 2014.
20. Ahmad I and Rao DN: Chemistry and biology of DNA methyltransferases. Crit Rev Biochem Mol Biol 31:361-380, 1996.
21. Gardiner-Garden M and Frommer M: CpG islands in vertebrate genomes. J Mol Biol 196:261-282, 1987.
22. Cottrell SE: Molecular diagnostic applications of DNA methylation technology. Clin Biochem 37:595-604, 2004.
23. Stresemann C, Brueckner B, Musch T, Stopper H and Lyko F: Functional diversity of DNA methyltransferase inhibitors in human cancer cell lines. Cancer Res 66:2794-2800, 2006.
24. Sitwala KV, Adams K and Markovitz DM: YY1 and NF-Y binding sites regulate the transcriptional activity of the dek and dek-can promoter. Oncogene 21:8862-8870, 2002.
25. Carro MS, Spiga FM, Quarto M, Di Ninni V, Volorio S, Alcalay M and Müller H: DEK Expression is controlled by E2F and deregulated in diverse tumor types. Cell Cycle 5:1202-1207, 2006.
26. Lü ZL, Luo DZ and Wen JM: Expression and significance of tumor-related genes in HCC. World J Gastroenterol 11:3850-3854, 2005.
27. Lin LJ and Chen LT: The role of DEK protein in hepatocellular carcinoma for progression and prognosis. Pak J Med Sci 29:778-782, 2013.
28. Yi HC, Liu YL, You P, Pan JS, Zhou JY, Liu ZJ and Zhang ZY: Overexpression of DEK gene is correlated with poor prognosis in hepatocellular carcinoma. Mol Med Rep 11:1318-1323, 2015.
29. Kondoh N, Wakatsuki T, Ryo A, Hada A, Aihara T, Horiuchi S, Goseki N, Matsubara O, Takenaka K, Shichita M, et al: Identification and characterization of genes associated with human hepatocellular carcinogenesis. Cancer Res 59:4990-4996, 1999.
30. Roman-Gomez J, Jimenez-Velasco A, Agirre X, Cervantes F, Sanchez J, Garate L, Barrios M, Castillejo JA, Navarro G, Colomer D, et al: Promoter hypomethylation of the LINE-1 retrotransposable elements activates sense/antisense transcription and marks the progression of chronic myeloid leukemia. Oncogene 24:7213-7223, 2005.
31. Li S, Hansman R, Newbold R, Davis B, McLachlan JA and Barrett JC: Neonatal diethylstilbestrol exposure induces persistent elevation of c-fos expression and hypomethylation in its exon-4 in mouse uterus. Mol Carcinog 38:78-84, 2003.
32. Dang CV, O'donnell KA and Juopperi T: The great MYC escape in tumorigenesis. Cancer Cell 8:177-178, 2005.
33. Rodriguez BAT, Weng YI, Liu TM, Zuo T, Hsu PY, Lin CH, Cheng AL, Cui H, Yan PS and Huang TH: Estrogen-mediated epigenetic repression of the imprinted gene cyclin-dependent kinase inhibitor 1C in breast cancer cells. Carcinogenesis 32:812-821, 2011.
34. Sato N, Maitra A, Fukushima N, van Heek NT, Matsubayashi H, Iacobuzio-Donahue CA, Rosty C and Goggins M: Frequent hypomethylation of multiple genes overexpressed in pancreatic ductal adenocarcinoma. Cancer Res 63:4158-4166, 2003.